Zosano Pharma (ZSAN) Completes Enrollment in Zotrip Trial
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Zosano Pharma Corporation (Nasdaq: ZSAN) announced completion of enrollment in its registration-enabling, pivotal efficacy trial (the Zotrip trial), of M207 for the treatment of acute migraine.
“The completion of enrollment in the Zotrip study is a major milestone for the Company and bolsters our confidence in the previously announced availability of trial data in the first quarter of 2017,” commented Konstantinos Alataris, PhD, President and Chief Executive Officer of Zosano Pharma. “The enrollment pace is also indicative of the urgent need for improved treatment options for those suffering with acute migraine.”
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cellceutix Corporation (CTIX) Commences Second Cohort of Brilacidin Phase 2 in IBD
- Omeros (OMER) Presents Positive Results from OMS721 Phase 2 in HSCT-TMA
- UPDATE: Linde to Resume Talks with Praxair (PX); Appoints Belloni as CEO
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!